Business
Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting
MARLBOROUGH, Mass., June 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"MARLBOROUGH, Mass., June 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented a trial-in-progress poster describing the study outline of its Phase 1b clinical trial of PH-762, a self-delivering RNAi targeting PD-1, for the treatment of advanced melanoma at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, which is being held June 3-7, 2022 in Chicago, IL.\nLogo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg\nImmunotherapy with antibodies targeting immune checkpoints, such as PD-1, has shown significant benefit in late stage melanoma patients. However, further improvements in therapeutic options are still needed. Treatment given as a first step prior to surgery, or neoadjuvant treatment, and local intratumoral (IT) injection are two alternative approaches for improving the outcome of immunotherapy for melanoma patients.\n\"We are pleased to share the details for the ongoing clinical trial of our lead product, PH-762. As the first-in-human study for an INTASYL immunotherapy compound, the initiation of this study earlier this year marks an important milestone for our broader pipeline and platform,\" said Dr. Simon Fricker, Phio's VP of Research and Development. \"Neoadjuvant therapy may stimulate significant responses that appear to be associated with a decrease in the risk of relapse after surgery. As there is currently no neoadjuvant standard of care for resectable advanced melanoma patients, neoadjuvant treatment with PH-762 provides an alternative therapeutic option to treat these patients.\"\nIT administration of PH-762 to the tumor can stimulate a local immune response in the tumor microenvironment by silencing PD-1 and generating an immune response in distant untreated tumors. Studies conducted by the Company have shown potent silencing of PD-1 and a robust, dose-dependent inhibition of tumor growth. Further, IT injection of PH-762 also has the potential to minimize systemic effects and off-target toxicity, which has been seen with the use of antibodies.\nThe poster presented at ASCO outlines the design of the Phase 1b study with PH-762 for the treatment of patients with advanced melanoma....